BF Biosciences has introduced Zeptide in Pakistan.
According to details, Pakistan’s leading biopharmaceutical manufacturer, BF Biosciences, has launched its innovative drug Zeptide for the treatment of Type 2 Diabetes and obesity. Zeptide is a modern and advanced treatment for Type 2 Diabetes and obesity.
Zeptide provides a safe and convenient solution, available in a pre filled syringe form.
According to a notice issued by BF Biosciences to the Pakistan Stock Exchange, Zeptide is an FDA approved synthetic polypeptide that acts equally on both GLP-1 and GIP receptors.
It represents a significant advancement in regulating blood glucose levels and promoting weight reduction.
The new Zeptide pre filled syringe is manufactured at BF Biosciences’ state-of-the-art plant based on European technology, ensuring dosage accuracy, safe use, and ease for patients.
According to the company’s statement, the composition, quality, and potency of Zeptide have been verified by a renowned biological mass spectrometry laboratory in the United States and a leading Pakistani university, validating it on an international level.
The success of the new Zeptide has been achieved under the effective utilization plan of the capital raised through the company’s IPO, reflecting BF Biosciences’ commitment to investing in Pakistan’s healthcare system.
As Pakistan’s first biopharmaceutical plant, BF Biosciences Limited has, for over a decade, been producing essential medicines for the treatment of HCV, cancer, cardiovascular diseases, diabetes, nephrology, and other critical illnesses.
